1.      King H, Aubert R E, Herman W H. Global burden of Diabetes .1995-2025: Preval-ence. Numerical estimates and Projections. Diabetes Care 1998; 21; 1414-1431

2.      John, H.J: Hypertension and Diabetes , Ann Intern Med.1932, June; 5:1462-1486 

3.      American Diabetes Association, Standards of     Medical Care in Diabetes. Diabetes Care  2012 Jan 35 : S11-S63

4.      Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and   Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Executive Summary. May 2001. NIH 01-3670.

5.      McFarlane S I, Sowers J R, Cardiovascular endocrinology 1: Aldosterone function in diabetes mellitus: effects on cardiovascular and renal disease. J. Clin. Endocrinol. Metab. 2003; 88(2): 516–523.

6.      Westerbacka J, Vehkavaara S, Bergholm R, Wilkinson I, Cockcroft J et al. Marked resistance of the ability of insulin to decrease arterial stiffness characterizes human obesity .Diabetes .1999;48(4):  821–827.

7.      Hypertension in Diabetes Study Group HDS. 1. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardio-vascular and diabetic complicat-ions. JHypertens. 1993;11:309–317

8.      Begum N, Duddy N, Sandu O, Reinzie J, Ragolia L. Regulation of myosin bound protein phosphatase by insulin in vascular smooth muscle cells. Evaluation of the role of Rho kinase and PI3-kinase dependent signaling pathways. Mol Endocrinol 2000;14: 1365–1376

9.      Lorcnzi M, Cagliero E, Toledo S: Glucose toxicity for human endothelial cells in culture: Delayed replication, disturbed cell cycle and accelerated death. Diabetes 1985;34:621-627

10.  Roy S, Sala R, Cagliero E, Lorenzi M: Overexpression of fibronectin induced by diabetes or high glucose: Phenomenon with a memory. Proc Natl Acad Set 1990;87:404-408

11.  Cerami A, Vlassara H, Brownlee M: Protein glycosylation and the pathogenesis of atherosclerosis. Metabolism. 1985; 34:37-4

12.  Weir M. Diabetes and hypertension: how low should you go and with which drugs? Am J Hypertens. 2001; 14:17S-26S. 

13.  Tai TY, Chuang LM. Link between Hypertension and Diabetes Mellitus Epidemiological Study of Chinese Adults in Taiwan. Diabetes Care. 1991; 14:1013-20.

14.  Ginsberg HN. Diabetic dyslipidemia: Basic mechanisms underlying the common hypertriglyceridemia and low HDL cholesterol levels. Diabetes.1996; 45( 3):S27–S30

15.  Lewis GF, Uffelman KD, Szeto LW, Weller B, Steiner G. Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest.1995; 95:158–166

16.  Knutson VP. The release of lipoprotein lipase from 3T3–L1 adipocytes is regulated by microvessel endothelial cells in an insulin-dependent manner. Endocrinology.2000; 141:693–701.

17.  Tavangar K, Murata Y, Pedersen ME, Goers JF, Hoffman AR et al. Regulation of lipoprotein lipase in the diabetic rat. J Clin Invest.1992; 90:1672–1678.

18.  De Man FH, Cabezas MC, Van Barlingen HH, Erkelens DW, de Bruin TW. Triglyceride-rich lipoproteins in non-insulin-dependent diabetes mellitus: post-prandial metabolism and relation to premature atherosclerosis. Eur J Clin Invest.1996; 26:89–108.

19.  American Diabetes Association Diagnosis and Classification of Diabetes Mellitus. Diabetes Care.2012,Jan; 35: S 64-71

20.  Schwartz S L . Diabetes and dyslipidemia: Diabetes Obes Metab; 2006,8(4):355-64.